Abstract Number: 239 • 2019 ACR/ARP Annual Meeting
The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia
Background/Purpose: The SELENA-SLEDAI is a tool for measuring the activity of systemic lupus. It is frequently used in clinical drug trials, but what is the…Abstract Number: 240 • 2019 ACR/ARP Annual Meeting
Whom Do Patients with Fibromyalgia Turn to for Emotional Support?
Background/Purpose: Fibromyalgia patients often have intense symptoms, especially pain and fatigue. We asked them in an in-office questionnaire whom they turn to for emotional support.Methods:…Abstract Number: 241 • 2019 ACR/ARP Annual Meeting
Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise
Background/Purpose: Exercise is reported to help patients with the fibromyalgia syndrome (FMS). We wanted to know whether FMS patients, compared to non-FMS rheumatic disease patients,…Abstract Number: 242 • 2019 ACR/ARP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Background/Purpose: To assess patients’ global assessment of frequently used treatments for the fibromyalgia syndrome (FMS), we asked patients with fibromyalgia to rank medications they have…Abstract Number: 243 • 2019 ACR/ARP Annual Meeting
Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment
Background/Purpose: Some rheumatic disease patients have concomitant fibromyalgia. We wanted to determine treatment response in patients with and without concomitant fibromyalgia.Methods: Patients were diagnosed by…Abstract Number: 244 • 2019 ACR/ARP Annual Meeting
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Background/Purpose: SLE is an autoimmune multi-system disease characterized by flares and more rarely remissions. Emerging biologic therapies for SLE are expected to change the treatment…Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…Abstract Number: 247 • 2019 ACR/ARP Annual Meeting
Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Background/Purpose: To determine health literacy, medication adherence, and quality of life (QOL) of uveitis patients in order to understand how to deliver better and improved…Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…Abstract Number: 251 • 2019 ACR/ARP Annual Meeting
Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
Background/Purpose: Biosimilars have enabled some US institutions and payers to achieve significant financial savings after implementing a formulary change from the reference biologic. However, within…Abstract Number: 252 • 2019 ACR/ARP Annual Meeting
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
ACR Meeting Abstracts